Xtant Medical Holdings reported ineffective disclosure controls due to an inventory valuation material weakness as of September 30, 2026. It lost $16.1 million and used $10.3 million in operating activities during nine months, required covenant amendments, and withdrew 2026 guidance.
XTNT · Xtant Medical Holdings, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Xtant Medical launched a board-led strategic review after missing guidance for a second consecutive quarter. Third-quarter revenue was $24.3 million, net loss was $3.6 million, adjusted EBITDA was a loss of $1.5 million, and previously issued full-year 2026 guidance will not be achieved.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 11, 2026TL;DR. Xtant reported Q2 2026 revenue of $23.0M with a net loss of $9.4M and an adjusted EBITDA loss of $2.7M, lowered full-year 2026 revenue guidance to $99–$103M (from $101–$105M), while advancing the Dilon/HEMOBLAST distribution agreement and launching Trivium Shaped.
- + Acquired exclusive U.S. distribution rights to Dilon's HEMOBLAST Bellows, adding entry into an estimated $1B hemostatic TAM and a 17-rep specialty Salesforce
- + Launched Trivium Shaped in May with strong early sales traction, extending the Trivium DBM bone graft portfolio
- + Hardware revenue was higher than anticipated in Q2, driven by sales of the Corterra spinal fixation system
- − Gross margin compressed to 57.9% from 68.6% due to cessation of high-margin Q-code license revenue, reduced production efficiencies, and higher excess/obsolete inventory charges
- − Q2 operating expenses rose to $22.5M from $19.7M, driven by a $5.0M exclusivity fee paid to Dilon Technologies
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP Adjusted EBITDA non-GAAP | -4.26M | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted EBITDA loss non-GAAP | 2.7M | second quarter of 2026 | — |
| Non-GAAP Adjusted EBITDA/Total Revenue non-GAAP | -11.6% | Three Months Ended June 30, 2026 | — |
| Non-GAAP EBITDA non-GAAP | -10.44M | Six Months Ended June 30, 2026 | — |
| Non-GAAP EBITDA/Total Revenue non-GAAP | -36% | Three Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XTNT
this stock
Xtant Medical Holdings, Inc.
|
$38.12M | -65.2% | -17.5% | — | 0.3% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 15
Xtant Medical launched a board-led strategic review after missing guidance for a second consecutive quarter. Third-quarter revenue was $24.3 million, net loss was $3.6 million, adjusted EBITDA was a loss of $1.5 million, and previously issued full-year 2026 guidance will not be achieved.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XTNT | -6.1% | -5.2% | -40.9% | -3.0% | -65.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -8.7% | -4.1% | -41.4% | -2.9% | -75.8% |